Intra-Cellular Therapies (ITCI) Insider Trading & Ownership $131.87 0.00 (0.00%) As of 04/2/2025 Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Intra-Cellular Therapies (NASDAQ:ITCI) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage2.60%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)5Amount OfInsider Selling(Last 12 Months)$21.31 M Get ITCI Insider Trade Alerts Want to know when executives and insiders are buying or selling Intra-Cellular Therapies stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ITCI Insider Buying and Selling by Quarter Intra-Cellular Therapies Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails3/24/2025Gilbert Ray Cisneros, Jr.U.S. Congress Member (D-CA)Sell$131.70$1,001 - $15,0003/17/2025Josh GottheimerU.S. Congress Member (D-NJ)Sell$131.45$1,001 - $15,0001/24/2025Josh GottheimerU.S. Congress Member (D-NJ)Sell$127.35$1,001 - $15,00012/4/2024Sharon MatesCEOSell51,000$85.80$4,375,800.00 11/12/2024Michael HalsteadPresidentSell22,869$89.12$2,038,085.28 8/30/2024Sharon MatesCEOSell34,396$72.84$2,505,404.64 8/27/2024Sharon MatesCEOSell40,513$73.58$2,980,946.54 8/23/2024Sharon MatesCEOSell28,680$74.46$2,135,512.80 8/21/2024Sharon MatesCEOSell53,013$75.65$4,010,433.45 8/16/2024Mark NeumannEVPSell18,714$75.08$1,405,047.12 6/24/2024Rory B RiggsDirectorSell4,462$75.57$337,193.34 6/21/2024Josh GottheimerU.S. Congress Member (D-NJ)Sell$76.58$1,001 - $15,0006/18/2024Nostrand Robert L VanDirectorSell20,000$75.91$1,518,200.00 (Data available from 1/1/2013 forward) ITCI Insider Trading Activity - Frequently Asked Questions Who is on Intra-Cellular Therapies's Insider Roster? The list of insiders at Intra-Cellular Therapies includes Joel S Marcus, Lawrence J. Hineline, Mark Neumann, Michael Halstead, Nostrand Robert L Van, Rory B Riggs, Sharon Mates, Suresh K Durgam. Learn more on insiders at ITCI. What percentage of Intra-Cellular Therapies stock is owned by insiders? 2.60% of Intra-Cellular Therapies stock is owned by insiders. Learn more on ITCI's insider holdings. Which Intra-Cellular Therapies insiders have been selling company stock? The following insiders have sold ITCI shares in the last 24 months: Joel S Marcus ($1,808,207.04), Lawrence J. Hineline ($7,704,360.65), Mark Neumann ($7,014,456.71), Michael Halstead ($6,413,908.64), Nostrand Robert L Van ($1,518,200.00), Rory B Riggs ($337,193.34), Sharon Mates ($34,116,938.78), and Suresh K Durgam ($549,042.00). How much insider selling is happening at Intra-Cellular Therapies? Insiders have sold a total of 955,932 Intra-Cellular Therapies shares in the last 24 months for a total of $65,241,446.36 sold. Which members of congress are trading Intra-Cellular Therapies? Gilbert Ray Cisneros, Jr. (D-CA) and Josh Gottheimer (D-NJ) have sold shares of Intra-Cellular Therapies in the last year totaling $32,000. Intra-Cellular Therapies Key ExecutivesDr. Sharon Mates Ph.D. (Age 71)Co-Founder, Chairman & CEO Compensation: $2.23MMr. Michael I. Halstead J.D. (Age 51)President Compensation: $983.65k1 recent tradesDr. Suresh K. Durgam M.D. (Age 55)Executive VP & Chief Medical Officer Compensation: $961.84kMr. Mark Neumann (Age 61)EVP & Chief Commercial Officer Compensation: $998.36kDr. Robert E. Davis Ph.D. (Age 73)Senior VP & Chief Scientific Officer Compensation: $646.12kMr. Juan Fernando Sanchez (Age 53)Vice President of Corporate Communications & Investor Relations Compensation: $296.75kMs. Karen Patruno Sheehy Esq. (Age 62)Senior VP & Chief Compliance Officer Dr. Michael OlchaskeySenior VP & Head of Regulatory AffairsMr. John A. BardiSenior VP of Market Access, Policy & Government AffairsDr. Willie R. Earley M.D.Senior VP & Head of Clinical Development More Insider Trading Tools from MarketBeat Related Companies Takeda Pharmaceutical Insider Transactions argenx Insider Transactions BioNTech Insider Transactions Beigene Insider Transactions Summit Therapeutics Insider Transactions Teva Pharmaceutical Industries Insider Transactions Genmab A/S Insider Transactions Moderna Insider Transactions Viatris Insider Transactions Roivant Sciences Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 5 Mid-Cap Stocks Insiders Are Buying This YearInsider Buying in This Stock Reiterates Analysts Bullish OutlookBeware of BigBear.ai: Insiders Are Selling—Should You?XPO Buying $50 Million of Its Own Stock: Here's Why Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold This page (NASDAQ:ITCI) was last updated on 4/30/2025 by MarketBeat.com Staff From Our Partners"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredChina’s next move could destroy U.S. techThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intra-Cellular Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intra-Cellular Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
